Hybrid Artificial Pancreas in Home Setting

Inclusion Criteria: 1. Age ≥ 18 et \< 70 years old 2. Having diabetes according to WHO criteria for at least 6 months, and Type 1 diabetes according to ADA criteria 3. Under basal-bolus insulin therapy using an external insulin pump for at least 3 months 4. BMI \< 35 kg/m² 5. Willing to wear a CGM device for the whole duration of the study, except during washout period, combined with the DiAs platform during the evening and night-time for 2 months 6. Trained in carbohydrate counting 7. HbA1c \> 7.5 % and \< 10% 8. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, stability on the medication for at least 1 month prior to study inclusion 9. Willing to undergo all study procedures 10. Informed consent signed Exclusion criteria: 1. Pregnancy or breast feeding, or intention to be pregnant during the study duration 2. Use of a medication that significantly impacts glucose metabolism, e.g. steroids 3. Uncontrolled hypertension with resting blood pressure over 140/90 mmHg 4. Patient plans to go abroad during the trial period 5. Patient is expected to be out-of-home in the evening and during night time (e.g. shift-workers, etc.) more than 25% of a study period 6. Patient does not hold any nearby party for assistance if needed 7. Patient with severe hypoglycemia including coma, mental confusion and/or convulsions requesting IV glucose injection or glucagon injection during the last year. 8. Presence of any malignant disease, unless considered as cured for more than 10 years 9. History of acute cardiovascular event during the prior year 10. History of diabetic keto-acidosis during the prior 6 months 11. Renal insufficiency with creatinin \> 150 μmol/L 12. Impairment of liver status estimated from ASAT/ALAT plasma levels \> 2x upper limits of normal values 13. Impaired cognitive or psychological abilities which may result in defective adherence to study conditions